Blog

On December 16, 2020, the BEAMER project officially kicked off to find a new and effective way to resolve the longstanding and costly issue of non-adherence to treatment. Different from earlier initiatives and existing solutions to improve adherence to treatment, this project will focus on delivering a human behavioral based model based on for patients and healthcare professionals actionable...

Read more

When discussing patient adherence during clinical trials, most people will say that on average it is high and that the issue of non-adherence really surfaces during clinical care. But is this true or are we missing something in clinical trials? I think we are missing something, and the issue is far greater than we think it is. Early drop-out during clinical trials has always been and still...

Read more

The pharmaceutical industry is steadily moving forward on the introduction of virtuaal and hybrid clinical trials, and the healthcare industry in general is adopting more and more digital remote healthcare solutions to meet patients’ health-related preferences and at the same time overcome the challenges of social distancing and limited human interaction. It is indisputably true that...

Read more

In a previous article we had established that the key reasons for early drop-out have to do with misconceptions and wrong expectations. And that when we communicate information with patients, we clearly are not hitting the target. If we want to understand how we can make communication with patients more effective, we first need to understand what information is and what it can...

Read more

In 2018 global spending on drug development is expected to reach $172 billion[1] and that number will hit $204 billion by 2024. Clinical studies account for 45-75% of these costs[2]. In 2012 the life sciences industry was already spending $1.2 billion[3] on patient recruitment alone! Of these studies 85% fail to retain enough patients[4] and 95% fail to meet the original timeline and...

Read more

Years ago, I shared an editorial article from Nature on LinkedIn about the value and importance of true patient engagement in clinical trials. Involving patients from the earliest start of the clinical trial can and will lead to more effective and feasible clinical trial protocols. Patients are equivalent partners, and researchers need to incorporate patient feedback into the protocol. The...

Read more

Over 95% of the clinical studies fail to meet their original time lines and budgets.[1] Between 2006 and 2016 the global spending on drug development grew from $108 billion to over $148 billion.[2] Clinical trials account for 45% to 75% of this cost[3] and in 2012 the life sciences industry was already spending $1.2 billion[4] on patient recruitment alone! It is a well-known fact that delays...

Read more

The more I read about patient centricity, the more I get the eerie feeling that there is something wrong, something missing. At first glance the concept is very clear, the strategy and tactics are right and the tools put to use all have an added value. But it still doesn’t feel quite right to me. So what is it? Being responsible for business development, I fully understand why the...

Read more